Clinicopathological characteristics of circumscribed high-grade astrocytomas with an unusual combination of BRAF V600E, ATRX, and CDKN2A/B alternations. by 村上, 千明 et al.
Vol.:(0123456789) 
Brain Tumor Pathology 
https://doi.org/10.1007/s10014-019-00344-z
ORIGINAL ARTICLE
Clinicopathological characteristics of circumscribed high‑grade 
astrocytomas with an unusual combination of BRAF V600E, ATRX, 
and CDKN2A/B alternations
Chiaki Murakami1  · Yuka Yoshida1 · Tatsuya Yamazaki1 · Ayako Yamazaki1 · Satoshi Nakata2 · Yohei Hokama3 · 
Shogo Ishiuchi3 · Jiro Akimoto4 · Yukiko Shishido‑Hara5 · Yuhei Yoshimoto2 · Nozomi Matsumura1 · 
Sumihito Nobusawa1 · Hayato Ikota1 · Hideaki Yokoo1
Received: 12 March 2019 / Accepted: 27 March 2019 
© The Japan Society of Brain Tumor Pathology 2019
Abstract
We report four cases of high-grade astrocytoma with a BRAF V600E mutation, ATRX inactivation, and CDKN2A/B homozy-
gous deletion. Children to young adults aged 3–46 presented with a well demarcated contrast-enhancing mass in the supraten-
torial area. Pathological examination revealed packed growth of short spindle to round polygonal cells including some 
pleomorphic cells. The tumors had less ability to infiltrate into the adjacent brain parenchyma and presented a circumscribed 
growth pattern. Mitosis was readily found, accompanied by focal necrosis and/or microvascular proliferation. Tumors were 
histologically similar in part to pleomorphic xanthoastrocytoma (PXA) or anaplastic PXA, but did not fit criteria for either 
neoplasm. A BRAF V600E mutation and homozygous deletion of CDKN2A/B were observed, which is similar to the genetic 
features of PXA or epithelioid glioblastoma, but the additional loss of ATRX nuclear immunoreactivity and absence of TERT 
promoter mutation were unusual findings, indicating a novel genetic profile. Despite their malignant histological features, 
all patients had a favorable clinical course and remained alive for 6 months to 28 years under standard medical treatment for 
malignant glioma. In summary, high grade astrocytomas with BRAF V600E, ATRX, and CDKN2A/B alternations had unique 
clinicopathological features and may be a novel subset of high grade glioma.
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Introduction
Astrocytic tumors can be separated by their growth pattern, 
either diffuse or localized. Diffuse astrocytic tumors include 
diffuse astrocytoma, anaplastic astrocytoma, and glioblas-
toma. These tumors are mainly located in the supratentorial 
white matter and are characterized by diffuse infiltration. 
Localized astrocytomas, such as pilocytic astrocytoma and 
pleomorphic xanthoastrocytoma (PXA), have less ability 
to infiltrate into the adjacent brain parenchyma and tend to 
show a solid growth pattern in the subarachnoid space. Dif-
fuse astrocytic tumors have an IDH1/2 mutation, frequent 
inactivation of ATRX, and mutation of TP53, whereas local-
ized astrocytomas tend to have mutations in the MAPK path-
way such as BRAF.
PXA with increased mitotic activity (≧ 5 mitoses per 
10 high-powered fields) was recognized by the WHO clas-
sification criteria in 2016 as anaplastic PXA (A-PXA). 
A-PXAs have typical histological features of PXA, such as 
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proliferation of spindle-shaped cells with intermingled pleo-
morphic cells or xanthomatous cells, abundant eosinophilic 
granular bodies, and rich pericellular reticulin fibers [1]. 
PXA and A-PXA commonly have a BRAF V600E mutation 
and a homozygous deletion of CDKN2A/B. Moreover, TERT 
promoter mutations occasionally occur in PXA (20.5% in 
PXA, 23–47% in A-PXA) [2, 3], but ATRX inactivation is 
rare.
Here, we report four cases of high grade astrocytomas 
with an unusual combination of a BRAF V600E mutation, 
CDKN2A/B homozygous deletion, and ATRX inactivation. 
We discuss the histopathological differences between these 
tumors and other astrocytic tumors including PXA.
Materials and methods
Tumor samples
Four cases of high-grade astrocytoma, which had ATRX 
inactivation and BRAF V600E mutation by immunohisto-
chemistry and DNA sequence, were recruited. Two cases 
were from the pathology archives of the Department of 
Pathology, Gunma University Hospital. One was reported 
previously (Case 2) [4]. The other two cases were from the 
pathology archives of the Tokyo Medical University Hospi-
tal and the University of Ryukyus Graduate School of Medi-
cine. This research was approved by the ethics committee of 
Gunma University.
Clinical data
Clinical data and images were obtained from the charts and 
clinicians of each hospital.
Conventional histological analysis
Tissue specimens were fixed in 10% formalin and embed-
ded in paraffin. Three-micrometer-thick tissue sections 
were stained with hematoxylin and eosin. For immunohis-
tochemistry, the following primary antibodies were used: 
Glial fibrillary acidic protein (GFAP; polyclonal, 1:5,000: 
our own), Olig2 (polyclonal, 1:5000; IBL, Takasaki, Japan), 
S-100 protein (polyclonal, 1:10,000; our own), Nestin (mon-
oclonal, 1:200; Merck Millipore, Billerica, MA, USA), 
CD34 (monoclonal, 1:200; Nichirei, Tokyo, Japan), p53 
protein (monoclonal, 1:50; Leica Microsystems, Wetzlar, 
Germany), ATRX (polyclonal, 1:500; Sigma, St. Louis, MO, 
USA), BRAF V600E epitope (monoclonal, 1:50; Spring 
Bioscience, Pleasanton, CA, USA), Isocitrate dehydrogenase 
1 (IDH1)-R132H (monoclonal, 1:50; Dianova, Hamburg, 
Germany), and Ki-67 (MIB-1; monoclonal, 1:100; Dako). 
For GFAP, S-100P, Nestin, Olig2, EMA, CD34, ATRX, 
and BRAF V600E, the intensity of the staining was graded 
as negative, weak, moderate or strong, and the extent was 
scored as follows: (−) totally negative (1+ ) < 10% of tumor 
cells were positive (2+ ) 10–50% of tumor cells were posi-
tive, and (3+ ) more than 50% of tumor cells were positive. 
The Ki-67 labeling index (LI) was measured by Gunma-LI 
(Version 017; Japan Brain Tumor Reference Center, Gunma, 
Japan; available at https ://www.jbtrc .com/05_mib04 .php).
Direct DNA sequencing for BRAF, IDH1/2, TP53, 
and TERT promoter mutations
DNA was extracted from paraffin sections as previously 
described [5] and was amplified and sequenced using the 
primers described previously [6–9] (Supplementary mate-
rial, Table 1). PCR products were sequenced on a 3130xl 
Genetic Analyser (Applied Biosystems, Foster City, CA, 
USA) with the Big Dye Terminator v.1.1 Cycle Sequenc-
ing kit (Applied Biosystems) following standard procedures.
Multiplex ligation‑dependent probe amplification 
(MLPA) analysis
Copy number changes in the CDKN2A/B genes and chro-
mosomes 1 and 19 were analyzed by multiplex ligation-
dependent probe amplification (MLPA) as described previ-
ously [10].
Results
Clinical findings
The clinical features of each case are shown in Table 1. 
There were three females and one male. Their age of onset 
ranged from 3 to 41 years. The symptoms at presentation 
were headache, epilepsy, impaired consciousness, and 
facial spasm. Imaging features revealed similar findings 
in all cases. The tumors were located within the cerebral 
hemispheres; cases 1, 2, and 4 in the temporal lobe, and 
case 3 in the frontal lobe. The examination of gadolinium-
enhanced T1-weighted magnetic resonance imaging (MRI) 
revealed well demarcated, nodular, contrast-enhancing 
lesions (Fig. 1a, e, g, j). In the recurrent tumor of case 2, 
heterogeneous enhancement was observed (Fig. 1e), whereas 
other cases were uniformly enhanced (Fig. 1a, g, j). Mild 
to-moderate edema surrounding the tumor was observed by 
T2-weighted MRI (Fig. 1b, f, h, k). No calcification was 
detected by computed tomography (Fig. 1c, i, l). Gross total 
resection and adjuvant chemoradiotherapy was performed 
in all patients. The follow-up period from the first operation 
ranged from 6 months to 28 years. Case 1 and 2 recurred 
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23 years and 4 years after surgery, respectively, and all 
patients remained alive.
Histological findings
A summary of the histological features is presented in 
Table 2. The ratio of cellular elements was assayed by visual 
estimation. All tumors had a solid growth pattern, with case 
1, 2, and 3 showing a slight degree of infiltration to the adja-
cent brain parenchyma (Fig. 2a). In case 1, tumor extension 
along the parenchymal vessels and subpial accumulation of 
tumor cells was found (Fig. 2b). Medium-sized muscular 
arteries were entrapped in all cases, which suggests exo-
phytic tumor growth into the subpial space. 
All tumors were mainly composed of short spindle cells 
with round-to-oval nuclei and thick processes arranged in 
a fascicular pattern (Fig. 2c, d). Tumor cells with round 
cytoplasm and eccentric nuclei resembling epithelioid 
cells were occasionally seen (Fig. 2e). Large mono- or 
multi-nucleated pleomorphic cells were focally observed 
(Fig. 2f). A xanthomatous change was seen in case 2, 
but not conspicuous. Unlike conventional PXAs, eosino-
philic granular bodies were found only in case 4 (Fig. 2g), 
and not apparent in the other cases. Reticulin fibers sur-
rounding tumor cells were not observed by silver stain-
ing (Fig. 2h). Thick hyalinization of the vessel wall was 
found in case 2. Invasion of tumor cells into the vascular 
wall was seen in cases 3 and 4. Concentric fibrosis around 
blood vessels was observed in case 4. An increase of small 
vessels was observed in all cases, and a small number of 
microvascular proliferations was detected in cases 1, 4, 
and the recurrent tumor of case 2. Relatively high levels of 
mitotic activity were seen with brisk mitotic figures rang-
ing from 4 to 20 per 10 high-powered fields. Palisading 
necrosis was identified in cases 1 and 2 (Fig. 2i).
Immunohistochemistry
The immunohistochemical findings are summarized in 
Table 2. All tumors were diffusely positive for S-100 pro-
tein, Olig2, and Nestin (Fig. 3a, b). Spindle-shaped cells 
were diffusely-to-sparsely positive for GFAP (Fig. 3c). 
CD34 immunoreactivity was not detected in any tumors. 
Loss of ATRX nuclear expression (Fig. 3d) and BRAF 
V600E immunoreactivity and were observed in all cases 
(Fig. 3e). The Ki-67 labeling index ranged from 6.1 to 
20.1% (Gunma-LI) (Fig. 3f).
Genetic findings
A BRAF V600E mutation (Fig.  4a) and CDKN2A/B 
homozygous deletion (Fig. 4b) were detected in all cases 
by direct DNA sequencing or MLPA analysis. The TERT 
promoter and IDH1/2 were intact. Direct sequencing of 
TP53 revealed an R248Q mutation in case 3 (data not 
shown).
Table 1  Clinical features
(rec) recurrence, M male, F female, y.o. years old, MR (CE) magnetic resonance with contrast enhancement, GTR gross total resection, TMZ 
temozolomide
Case Age Sex Location Images Symptoms Treatment Prognosis
1 46 F Left temporal lobe Well demarcated mass 
on MR (CE) with 
focal edema; 6 × 4 cm
Epilepsy (41y.o.−), 
worsening headache 
(45y.o. −)
GTR, TMR +  radio-
chemotherapy
Recurrence (50y.o.), 
additional TMZ + beva-
cizumab, alive for 
7 years after first 
surgery
2 3 M Right temporal lobe Hemorrhagic mass 
with heterogeneous 
enhancement (only 
CT scan)
Impaired consciousness GTR, radiotherapy 
(33Gy) + platinum-
based chemotherapy
Recurrence (26y.o.)
2 (rec) 26 Right temporal lobe Heterogeneously 
enhanced mass on 
MR (CE) with focal 
surrounding edema; 
7 × 5 cm
Worsening headache Resection TMZ + beva-
cizumab
Alive for 5 years after 
second surgery
3 35 F Right frontal lobe Well demarcated mass 
on MR (CE) with 
focal edema
Left facial spasm, 
headache
GTR + radiother-
apy + TMZ
Alive without recurrence 
for a year
4 32 F Left temporal lobe Well demarcated mass 
on MR (CE) with 
focal edema
Headache GTR + radiother-
apy + TMZ
Alive without recurrence 
for 6 months
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Discussion
Alternation of ATRX in combination with BRAF V600E 
mutation and homozygous deletion of CDKN2A/B is very 
rare in gliomas. Among 681 grade I–IV gliomas in recent 
reports analyzing all three genetic mutations (82 adult glio-
blastomas, 148 grade II and III diffuse gliomas, 368 pedi-
atric low- and high-grade gliomas, 24 PXAs and A-PXAs, 
21 PAs and PAs with anaplasia, and 40 gangliogliomas) 
[11–23], only one case (histologically defined as anaplastic 
PXA) had all three mutations [11]. Five cases (three adult 
glioblastomas, one grade II diffuse glioma, and one pediatric 
GBM) had both BRAF V600E mutation and ATRX alter-
nation [17, 21, 22]. However, detailed histology was not 
reported in these studies. Moreover, we searched 2395 grade 
I–IV gliomas in a public database of The Cancer Genome 
Fig. 1  Radiological images 
of all four cases. Case 1 
(a–c). a Gadolinium-enhanced 
T1-weighted image (Gd-T1WI) 
shows a well demarcated mass 
by a homogeneous enhance-
ment. b A Fluid attenuated 
inversion recovery (FLAIR) 
image shows peritumoral 
edema. c Calcification was 
not detected by computed 
tomography (CT). Case 2 
(d–f). d Contrast-enhanced 
CT image of the initial onset 
when the patient was 3 years 
old. A circumscribed mass with 
hemorrhage was located within 
the right temporal lobe. e, f 
The recurrent tumor at age 26. 
e Gd-T1WI shows a hetero-
geneously enhanced tumor in 
the same region. f A FLAIR 
image shows a limited edema 
around the tumor. Case 3 (g–i). 
g Gd-T1WI shows a homogene-
ously enhanced circumscribed 
tumor in the right frontal lobe. 
h Surrounding edema was 
observed in the FLAIR image. 
i Calcification was not obvious 
in the CT image. Case 4 (j–l). j 
Gd-T1WI shows a well demar-
cated mass with a homogeneous 
contrast enhancement within the 
left temporal lobe. k A FLAIR 
image shows surrounding 
edema. l No calcification was 
detected in the CT image
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Atlas (TCGA) (cBioPortal for Cancer Genomics: https ://
www.cbiop ortal .org), but no tumor had all three alternations.
Reinhardt et al. recently reported a subset of histologi-
cally defined anaplastic pilocytic astrocytomas, showing a 
common DNA methylation profile [14]. These cases had a 
high frequency of shared mutations in the MAPK pathway, 
CDKN2A/B, and ATRX. Changes in the MAPK pathway 
were mostly a BRAF-KIAA1549 fusion or NF1 mutation, 
and only one case had the BRAF V600E mutation. The case 
with the BRAF V600E mutation also had a CDKN2A/B alter-
nation but no loss of ATRX immunoreactivity.
Both BRAF V600E mutation and CDKN2A/B homozy-
gous deletion commonly occur in PXA and A-PXA.[24, 25], 
whereas concurrent BRAF V600E mutation, CDKN2A/B 
Fig. 2  Histological findings. 
a Case 2. The border between 
the tumor and adjacent brain 
parenchyma was relatively 
sharp. b Case 1. Accumulation 
of tumor cells in the subpial 
and perivascular space. c, d 
Case 1. Proliferation of spindle 
cells in a fascicular pattern 
with frequent mitosis is shown 
(arrow). e Case 1. Tumor cells 
with eccentric nuclei and round 
cytoplasm resembled epithelioid 
cells. f Case 3. Pleomorphic 
cells with bizarre nuclei. g Case 
4. Eosinophilic granular bodies. 
h Case 1. Reticulin fibers were 
limited around blood vessels. 
i Case 2. Palisading necrosis. 
Scale bar = 50 µm (a–i)
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homozygous deletion, and TERT promoter mutation are 
frequent in epithelioid glioblastoma and A-PXA [10, 11]. 
In our current study, mutations in the TERT promoter were 
not detected, but loss of nuclear ATRX immunoreactivity 
was observed. This is interesting because TERT and ATRX 
are both telomere maintenance-related genes and are mutu-
ally exclusive in diffuse gliomas [26, 27]. Additionally, con-
current TERT promoter mutation, CDKN2A/B homozygous 
deletion, and BRAF V600E mutation are observed in a sub-
set of melanomas and thyroid carcinomas [28, 29], but the 
combination of ATRX inactivation, CDKN2/B homozygous 
deletion, and BRAF V600E mutation has not been reported 
in other non-CNS neoplasms.
Histologically, all of our cases had a solid growth pat-
tern, mainly composed of spindle-shaped cells with pleo-
morphism resembling PXA. A-PXA is sometimes misdiag-
nosed as glioblastoma or anaplastic astrocytoma because of 
its proliferative capacity [30]. In fact, tumors histologically 
diagnosed as A-PXA are occasionally re-classified into glio-
blastoma using methylation analysis [31]. The diagnosis of 
A-PXA can be supported not only by a demarcated border, 
but also numerous eosinophilic granular bodies, pleomor-
phic cells, and xanthic cells. In our cases, these histological 
features were not prominent, which made it more difficult to 
differentiate glioblastoma. However, all our cases resulted in 
an excellent post-operative state with the longest survival of 
28 years. Therefore, distinguishing these tumors from glio-
blastoma is important from a clinical aspect.
Previous studies of gliomas harboring BRAF V600E 
reported relatively favorable prognosis compared to those 
without this mutation [32–35]. Chi et al. reported five 
low-grade diffuse gliomas with the BRAF V600E muta-
tion demonstrating a distinct phenotype [36]. Several of 
these cases had relatively well demarcated borders. One 
Fig. 3  Immunohistochemi-
cal findings. a Uninterrupted 
nuclear immunoreactivity for 
Olig2. b Cytoplasmic positiv-
ity for Nestin. c GFAP was 
positive in patches. d The tumor 
cell nuclei show loss of ATRX 
expression, but expression in 
vessels was retained. e Diffuse 
moderate positivity for BRAF 
V600E. f Relatively high Ki-67 
labeling index is shown. a, b: 
case 4, c, f: case 3, d, e: case 1, 
Scale bar = 50 µm (a–f)
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case had packed growth of spindle-shaped glial cells with-
out typical characteristics of PXA, pilocytic astrocytoma, 
or ganglioglioma. The other case displayed proliferation 
of tumor cells in the subarachnoid and Virchow-Robin 
spaces. Although these cases were all low-grade, and 
the authors did not investigate mutations in ATRX and 
CDKN2A/B, the cases shared some clinicopathological 
features of our cases.
In summary, the present cases represent circumscribed 
high-grade astrocytomas with the unusual combination of 
BRAF V600E, ATRX, and CDKN2A/B alternations. These 
cases lacked typical histological characteristics of PXA 
and cannot be classified into the WHO classification of 
CNS tumors. Even with an anaplastic appearance, the 
prognosis was relatively favorable, and over-diagnosis of 
glioblastoma may be concerned. Alternations in ATRX and 
BRAF V600E can be readily detected by immunohisto-
chemistry to verify the diagnosis. To understand whether 
these tumors are a distinct entity, or they are a subgroup 
of other tumors such as PXA, more cases are needed, and 
additional methylation analysis is worth investigating.
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